Allecra Therapeutics, a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections. Allecra has a novel β-lactamase inhibitor in Phase 2 clinical development. By inhibiting β-lactamases Allecra’s new medicine directly tackles emerging resistance mechanisms of certain hard-to-treat bacteria. The product candidate has completed a pivotal phase III trial in cUTI showing superiority over standard of care
Location: France, Grand Est, Saint-Louis
Total raised: $44.35M
Investors 2
| Date | Name | Website |
| - | Forbion | forbion.co... |
| - | Andera Par... | anderapart... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.06.2016 | Series B | $24.78M | - |
| 18.04.2013 | Series A | $19.57M | Forbion |
Mentions in press and media 10
| Date | Title | Description |
| 13.06.2024 | Orchid to launch Enmetazobactum by next quarter | Orchid Pharma aims to launch its new drug, Enmetazobactum, by next quarter. The company received approval from the Drug Controller General of India last week, allowing it to manufacture and market the product in India. The company has since... |
| 10.03.2024 | Blockbuster BeiGene Cancer Drug Adds Another FDA Approval | A BeiGene drug already used to treat several types of blood cancer now has an additional FDA approval as a treatment for follicular lymphoma. The regulatory decision makes the BeiGene drug the first in its class for treating this type of ca... |
| 27.02.2024 | Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections | --Company Receives Five-year Exclusivity Extension Through GAIN Act -- SAINT-LOUIS, France & WEILL AM RHEIN, Germany, February 27, 2024 - Allecra Therapeutics (“Allecra”), a biopharmaceutical company developing novel therapies to combat... |
| 21.12.2020 | Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China | Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with a... |
| 21.12.2020 | Allecra Therapeutics GmbH : and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China | DGAP-News: Allecra Therapeutics GmbH / Key word(s): Agreement Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China 21.12.2020 / 08:00 The issuer is solel... |
| 26.03.2018 | Beating out market leaders in PhII, antibiotic-maker Allecra readies for Phase III trials | European biotech Allecra announced good news from the frontlines of its fight against multidrug-resistant gram-negative bacteria – some of the most dangerous superbugs around – after wrapping up a Phase II study of its in... |
| 15.06.2016 | Biopharmaceutical Company Allecra Therapeutics Closes €22M Series B Funding | Allecra Therapeutics, a Lorrach, Germany and Saint Louis, France-based biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, closed a €22M Series B funding round. The roun... |
| 15.06.2016 | Delos Capital Leads $24.7M Series B for Allecra Therapeutics | Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, announced today the closing of its €22 Million Series B investment round. The round was led b... |
| 18.04.2013 | Antibiotics upstart Allecra snags €15M VC round amid superbug scare | Amid an outcry for new options against drug-resistant bacteria, Allecra Therapeutics has taken off with a €15 million ($19.6 million) Series A round of venture financing. The startup plans to use the money to fund clinical development of a ... |
| 18.04.2013 | Allecra Therapeutics Inks EURO15M Series A | LORRACH, GERMANY and SAINT LOUIS, FRANCE, Biopharmaceutical company dedicated to the development of novel antibiotics to combat multi drug-resistant bacterial infections raised EURO15 million Series A financing. >> Click here for m... |